Equities

Oxford Nanopore Technologies PLC

ONT:LSE

Oxford Nanopore Technologies PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)141.00
  • Today's Change-5.20 / -3.56%
  • Shares traded1.21m
  • 1 Year change5.22%
  • Beta1.1554
Data delayed at least 20 minutes, as of Feb 06 2026 16:43 GMT.
More ▼

Forecasts data is unavailable for this security.

Consensus recommendation

  • 20-Feb-25
  • 20-Nov-25
  • 18-Dec-25
  • 15-Jan-26
  • 05-Feb-26
Select bar for recommendation details.
Recommendations05-Feb-26
Buy2
Outperform7
Hold3
Sell0
Strong Sell0

Share price forecast

The 11 analysts offering 12 month price targets for Oxford Nanopore Technologies PLC have a median target of 200.00, with a high estimate of 300.00 and a low estimate of 140.00. The median estimate represents a 41.84% increase from the last price of 141.00.
High112.8%300.00
Med41.8%200.00
Low-0.7%140.00

Earnings history & estimates

Oxford Nanopore Technologies PLC reported annual 2024 losses of -17.19 per share on Mar 04, 2025.
Average growth rate-14.11%
More ▼

Revenue history & estimates

Oxford Nanopore Technologies PLC had revenues for the full year 2024 of 183.19m. This was 7.97% above the prior year's results.
Average growth rate+14.00%
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.